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The most common inherited form of Frontotemporal
Lobar Degeneration (FTLD) known stems from Pro-
granulin (GRN) mutation and exhibits TDP-43 plus
ubiquitin aggregates. Despite the causative role of
GRN haploinsufficiency in FTLD-TDP, the neurobi-
ology of this secreted glycoprotein is unclear. Here,
we examined PGRN binding to the cell surface.
PGRN binds to cortical neurons via its C terminus,
and unbiased expression cloning identifies Sortilin
(Sort1) as a binding site. Sort1/ neurons exhibit
reduced PGRN binding. In the CNS, Sortilin is
expressed by neurons and PGRN is most strongly
expressed by activated microglial cells after injury.
Sortilin rapidly endocytoses and delivers PGRN to
lysosomes. Mice lacking Sortilin have elevations in
brain and serum PGRN levels of 2.5- to 5-fold. The
50% PGRN decrease causative in FTLD-TDP cases
is mimicked in GRN+/ mice, and is fully normalized
by Sort1 ablation. Sortilin-mediated PGRN endocy-
tosis is likely to play a central role in FTLD-TDP path-
ophysiology.
INTRODUCTION
The FTLDs are characterized clinically by dementia with promi-
nent behavioral alterations and distinct syndromes including
progressive aphasia and semantic disorders (Cairns et al.,
2007; Mackenzie et al., 2009). A subset of cases exhibit Tau-
positive neurofibrillary tangles, but the majority show TDP-43
and ubiquitin positive inclusions in the brain, termed FTLD-
TDP. TDP-43 aggregates and TDP-43 mutations are also
observed in ALS (Kabashi et al., 2008; Neumann et al., 2006;654 Neuron 68, 654–667, November 18, 2010 ª2010 Elsevier Inc.Sreedharan et al., 2008). Mutations in GRN are the most
common inherited cause of FTLD known (Baker et al., 2006;
Cruts et al., 2006; Gass et al., 2006). Such families exhibit auto-
somal-dominant inheritance of FTLD-TDP and their GRN muta-
tions result in loss of function. Levels of PGRN protein are
reduced by 50% in GRN mutant FTLD-TDP cases (Baker et al.,
2006; Cruts et al., 2006; Finch et al., 2009; Gass et al., 2006;
Ghidoni et al., 2008; Sleegers et al., 2009).
PGRN is an evolutionarily conserved, secreted glycoprotein
with 7 granulin (GRN) repeats. It has been implicated in wound
healing and is associated with malignancy, although the basis
for these effects is not fully defined (He et al., 2003; Zhu
et al., 2002). Effects of PGRN on neurite outgrowth or cell
survival in different assays have been reported (Van Damme
et al., 2008). However, in our preliminary studies, PGRN had
no detectable effects on the survival or neurite outgrowth
from cerebral cortical or hippocampal neurons (Figure S2 avail-
able online). While human haploinsufficiency results in FTLD-
TDP, mice homozygous for a GRN null mutation exhibit little
or no FTLD phenotype (Kayasuga et al., 2007; Yin et al.,
2010). As yet, there is no consensus regarding PGRN action
in the nervous system or the mechanism whereby 50% reduc-
tion might lead to FTLD-TDP. A fraction of PGRN can be
proteolytically processed to smaller GRN peptides (Zhu et al.,
2002), but the relative role of these fragments in FTLD-TDP is
not known.
Elucidation of PGRN action and the control of PGRN levels
may have broad relevance for both FTLD and ALS. In order
to advance understanding of secreted PGRN biology, we
searched for high-affinity cell surface binding sites in an unbi-
ased screen. We report that Sortilin is such a site and medi-
ates rapid endocytosis and lysosomal localization of PGRN.
Moreover, this mechanism has pronounced effects on brain
and serum PGRN levels that are as great as the haploinsuffi-
ciency causing FTLD-TDP. Thus, a Sortilin-dependent pathway
is likely to play a central role in FTLD-TDP, and possibly in
ALS.
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PGRN Binds with High Affinity to Sortilin
We hypothesized that the key step in PGRN action is binding to
neurons. We created an alkaline phosphatase (AP)-tagged
PGRN ligand to assess binding (Figure S1A). Fusion of the amino
terminus of PGRN to AP yields protein with high affinity for 21 DIV
cultured neurons (Figure 1A). Binding is saturable with an
apparent KD of 15.4 ± 2.5 nM (Figure 1B), and can be displaced
by unlabeled PGRN (Figure S1B).
Using this ligand binding assay, we searched for themolecular
identity of this site in anunbiased fashion by expression cloning in
COS-7 cells (Figure 1C). Untransfected COS-7 cells do not bind
AP-PGRN. After screening 225,000 clones at low stringency in
pools of 100, and 352 transmembrane proteins at high stringency
as single clones, we identified only one clone that supported
high affinity for AP-PGRN. This cDNA encodes Sortilin (Sort1),
a single-pass type I transmembrane protein of the Vps10 family
that is localized to the cell surface, secretory, and endocytic
compartments of eukaryotic cells (Willnow et al., 2008). The
affinity of AP-PGRN binding to Sortilin-expressing COS-7 cells
is indistinguishable from AP-PGRN binding to neurons (Figures
1D and 2C). Binding to Sortilin-expressing COS-7 cells is dis-
placed by excess unlabelled PGRN (Figure 2D).
The binding of PGRN to Sortilin-expressing cells appears to be
directed by several criteria. Bound PGRN localizes to Sortilin-
expressing cells and, at high magnification, PGRN colocalizes
extensively with cell surface Sortilin (Figure 1E). PGRN and
the ectodomain of Sortilin coimmunoprecipitate from the
conditioned medium of transfected cells, whereas an unrelated
secreted protein (Reg2) does not associate with the ectodomain
of Sortilin (Figure 1F). Furthermore, PGRN binding to Sortilin-
ectodomain-coated surface plasmon resonance (SPR) chips
exhibits an affinity similar to cellular binding (Figures 1G and
1H). Thus, Sortilin is identified as a direct high-affinity binding
site for PGRN.
Specificity of the Sortilin Interaction with PGRN
Sortilin and related proteins have been reported to bind several
ligands (Jansen et al., 2007; Nykjaer et al., 2004; Willnow et al.,
2008). SorLA, but not Sortilin, is implicated in APP processing
and Ab levels in Alzheimer disease (Andersen et al., 2005;
Rogaeva et al., 2007). Therefore, we expressed Sortilin-related
proteins, SorLA and SorCS1, in COS-7 cells and examined
PGRN binding. PGRN binds only to Sortilin (Figures 2A and
S1C). By SPR, SorLA, SorCS1, SorCS2, and SorCS3 exhibit
much lower affinity for PGRN than does Sortilin (Figure 2G).
Sortilin was originally identified as a low-affinity neurotensin
(NT) binding protein and termed NT receptor 3, or NTR3 (Willnow
et al., 2008). Two other NT binding sites are G protein-coupled
receptors, but NTR1 and NTR2 do not bind PGRN (Figures 2A
and S1C).
NT has recently been shown to complex with the Sortilin
b-propeller domain via its extreme C terminus (Quistgaard
et al., 2009), and the last six residues of NT displace PGRN
binding to Sortilin (Figures 2D and 2E). We considered a similar
model for PGRN and compared the Sortilin association of the
C-terminal 100 residues of PGRN, containing the GRN-E domainplus the extremeC-terminal residues (termed PGRN-E), with that
of the N-terminal 80% of the protein (termed PGRNDE). The
carboxyl PGRN-E segment fully accounts for PGRN interaction
with Sortilin. In fact, PGRN-E displays slightly higher affinity for
Sortilin than does full-length PGRN (Figures 1D, 2B, and 2C),
whereas the majority of the protein, contained in PGRNDE, has
no detectable affinity for Sortilin (Figure 2B).
Proneurotrophins, such as proNGF, are also reported ligands
of Sortilin, but they do not depend on the C terminus of the ligand
for binding to Sortilin, as do NT and PGRN (Domeniconi et al.,
2007; Jansen et al., 2007; Nykjaer et al., 2004; Teng et al.,
2005). While these ligands can reduce AP-PGRN binding to
Sortilin, inhibition requires very high levels of proNGF, in the
mM range (Figures 2D and 2E), with no inhibition by nM
concentrations (data not shown). In SPR competition assays,
proNGF and PGRN show additive binding signals for immobi-
lized Sortilin, consistent with distinct binding sites (Figure 2H).
ProNGF is reported to interact with a p75NTR/Sortilin complex
with enhanced bipartite affinity (Nykjaer et al., 2004). Therefore,
we examined AP-PGRN interaction with cell-expressing
p75NTR, Sortilin, or both (Figure 2F). PGRN shows no affinity
for p75NTR and the Sortilin/p75NTR coexpressing cells show
no enhancement of affinity for PGRN. Thus, the binding of
PGRN’s C terminus to Sortilin resembles a high-affinity version
of NT binding, but may be distinct from that of proneurotrophin
to Sortilin.
PGRN Binding to Neuronal Sortilin
A key issue is the extent to which Sortilin accounts for neuronal
binding sites for PGRN. Several criteria validate Sortilin as
a major PGRN binding in brain tissue. First, the development of
Sortilin parallels that of AP-PGRN binding sites. For embryonic
cortical neuron cultures at 7 DIV, both Sortilin expression and
PGRN binding sites are low, but both increase substantially by
14 DIV (Figures 3A and 3B). PGRN-E binds with equal or greater
affinity than does full-length PGRN to cortical neurons, whereas
PGRNDE does not bind to cortical neurons at 10 nM (Figures 3C
and S1D). Recombinant immobilized GST-PGRN-E, but not
GST, pulls down Sortilin from whole-brain extracts of wild-type
(WT), but not Sort1/, mice (Figure 3D). Sort1/mice produce
low levels of a misfolded Sortilin deletion mutant that lacks
a portion of the beta propeller region and does not bind
PGRN-E. Most critically, high-affinity AP-PGRN-E binding to
cortical neuron cultures from Sort1/ mice is significantly less
than that from WT mice (Figures 3E and 3F). This reduction is
prominent even after any potential compensatory upregulation
of alternate binding sites in the constitutive Sort1/ knockout
strain. Thus, Sortilin is a major high-affinity PGRN binding site
in cortical neurons.
Sortilin Regulates Extracellular PGRN Level
As a first step to explore possible effects of PGRN/Sortilin inter-
action, we coexpressed the two proteins in HEK293T cells.
PGRN is secreted from transfected cells, but when coexpressed
with Sortilin, PGRN levels in conditioned medium are dramati-
cally reduced to 15% of control levels (Figures 4A and 4B). It
has been reported that Sortilin can be a substrate for regulated
intramembranous proteolysis by gamma-secretase (HermeyNeuron 68, 654–667, November 18, 2010 ª2010 Elsevier Inc. 655
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Figure 1. Cellular Progranulin Binding Is Mediated by a Direct High-Affinity Interaction with Sortilin
(A) Cultured E18 rat hippocampal neurons at 21 days in vitro (21 DIV) were incubated with conditioned medium containing 50 nM AP-PGRN at 4C. Binding was
visualized with AP substrate BCIP/NBT.
(B) AP-PGRN binding to cortical neurons measured as a function of ligand concentration. Inset, Scatchard plot. KD, average ± SEM, n = 4 separate experiments.
(C) COS-7 cells transfected with Sortilin or vector control were incubated with conditioned medium containing 50 nM AP-PGRN.
(D) AP-PGRN binding to Sortilin expressing COS-7 cells measured as a function of AP-PGRN concentration.
(E) Binding of PGRN to Sortilin on COS-7 cell surface. Purified Flag-tagged PGRNwas incubated with COS-7 cells transfected with Myc-tagged Sortilin on ice for
2 hr. After washing, live cells were costained with mouse anti-Flag (green) and rabbit anti-Myc (red) antibodies on ice for 1 hr. Cells were then washed, fixed, and
stained with secondary antibodies, and counterstained with DAPI (blue). Note that PGRN binds only to Sortilin-expressing cells. In the high-magnification view of
a Sortilin-expressing cell in the bottom panels, there is extensive colocalization of the two proteins at the cell surface.
(F) Coimmunoprecipitation of Flag-PGRN with Myc-tagged ectodomain of Sortilin (Sort1-ecto). Conditioned media containing Flag-PGRN or Flag-Reg2 were
mixed together with conditioned media containing Myc-tagged Sort1-ecto protein. Immunoprecipitation (IP) was then carried out using anti-Myc or anti-Flag
antibodies as indicated. The presence of Sort1-ecto or Flag-tagged protein in the IP was detected in the immunoblot using anti-Myc or anti-Flag antibodies,
respectively.
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Sortilin-Mediated Endocytosis of Progranulinet al., 2006; Nyborg et al., 2006). From HEK cells, there is limited
secretion of a Sortilin proteolytic fragment into conditioned
medium, and this cleavage is not altered by PGRN coexpression
(Figure 4C).
The pronounced reduction in extracellular free PGRN caused
by Sortilin coexpression might be attributed to impaired secre-
tory trafficking within the cell, sequestration at the cell surface
via binding, or endocytosis and clearance from the medium.
Sortilin family proteins have been shown to play a role in both
trafficking and endocytosis for other ligands (Nielsen et al.,
2001; Willnow et al., 2008). To consider these possibilities, we
expressed mutants of Sortilin that lack the cytoplasmic tail of
the protein but carry an alternative C-terminal domain (pDisplay
Sort1) or that carry a mutation disrupting endocytosis and
possibly sorting (Sort1 mut) (Nielsen et al., 2001). While these
mutants traverse the secretory pathway and reach the cell
surface to support binding of AP-PGRN to transfected cells (Fig-
ure 6C, Movie S3, and data not shown), they do not alter PGRN
levels in conditioned medium (Figures 4A and 4B). A version of
Sortilin consisting only of the ectodomain (Sort1 ecto) is secreted
efficiently from transfected cells, but does not alter PGRN
level in the medium (Figures 4A and 4B). Furthermore, inhibition
of endocytosis by addition of 0.45 M sucrose to the culture
medium for 12 hr increases the level of PGRN in the medium of
Sortilin+PGRN-expressing cells to that of PGRN only cells
(data not shown). Thus, these initial studies suggested that the
reduced PGRN levels in conditioned medium from Sortilin coex-
pressing cells are due to endocytosis of PGRN.
Localization of PGRN to Activated Microglia
and Sortilin to Neurons
The potential roles of endocytic versus secretory pathways on
PGRN levels depend on whether PGRN and Sortilin are ex-
pressed in the same cells (cis) or different cell types (trans) in
brain. We examined frontal cortex for Sortilin and PGRN protein
localization. Both proteins exhibit intracellular granular immuno-
reactivity in cortical neuronal soma, but there is little colocaliza-
tion (Figure 5A). Sortilin and other members of the Vps10 family
are known to be enriched in recycling endosomes (Willnow
et al., 2008), consistent with this pattern. A vacuolar pattern for
PGRN has been reported in neurons and may reflect lysosomal
localization (see below). In Sort1/ brain, a similar pattern of
PGRN immunoreactivity is observed, but there is a trend toward
reduced vacuolar staining and increased diffuse neuropil stain-
ing (Figure 5B).
Previous studies have documented an unaltered PGRN distri-
bution in FTLD-TDP brain withGRNmutations (Mackenzie et al.,
2006). We examined Sortilin histologically in such cases (Baker
et al., 2006) (Figure 5C). The granular pattern of Sortilin inmmu-
noreactivity within frontal cortex neurons in healthy human
brain is similar to that seen in mouse brain. This distribution is
not altered in FTLD-TDP due to GRN mutation. Thus, these(G) Binding of PGRN to immobilized Sortilin ectodomain by surface plasmon reso
containing immobilized Sortilin (0.0952 pmol/mm2). The calculated KD value is in
(H) Purity of PGRN ligand for SPR studies. His-PGRN protein was purified by nick
analyzed by SDS-PAGE with Coomassie Blue staining. Migration of Mr standard
Scale bars, 50 mm for all, except 5 mm in the bottom panels of (E).steady-state localization studies of mouse and human frontal
cortex demonstrate that PGRN and Sortilin are present, but do
not provide mechanistic insight as to their roles.
To provide an experimental model that might mimic CNS
stress, repair, and regeneration in a manner relevant to FTLD
and ALS, we examined the ventral horn of the lumbar spinal
cord of mice after sciatic nerve injury. After axotomy, the protein
that aggregates in FTLD-TDP, TDP-43, shifts from a nuclear to
a cytoplasmic localization (Moisse et al., 2009; Sato et al.,
2009) (Figure S4). Sortilin is strongly expressed by spinal moto-
neurons (Figure 5D) (Domeniconi et al., 2007), but not by micro-
glia (Figure S7B). In contrast, PGRN is strongly induced in
activated microglial cells that surround motor neurons after
peripheral axonal injury, but not by astrocytes (Figures 5E, 5F,
and S3), consistent with human FTLD-TDP pathology (Baker
et al., 2006; Mackenzie et al., 2006). In naive tissue, PGRN
expression is much lower and includes a neuronal component
(Figures 5E and 5F and Ryan et al., 2009). These histological
studies, as well as previous expression surveys (Lein et al.,
2007; Su et al., 2004; Wu et al., 2009) (Figure S5), are most
supportive of the hypothesis that PGRN is secreted by activated
microglial cells and then interacts in trans with Sortilin on moto-
neurons to be endocytosed. Indeed, the C13-NJ microglial cell
line secretes PGRN robustly, but expresses little Sortilin
(Figure 5G).
Rapid Sortilin-Mediated Endocytosis of PGRN
to Lysosomes
Given the separate cells of origin, we focused on endocytosis of
PGRN by Sortilin in controlled systems. To visualize endocytosis
we expressed Sortilin in COS-7 cells and applied mCherry-
PGRN ligand (Figure 6A). At 4C, binding of fluorescent PGRN
ligand is detected at the cell surface and is extensively colocal-
ized with Sortilin. Cells were then shifted to 37C and the region
of the cell within 400 nm of the cell-attached surface was imaged
by total interference fluorescence microscopy (TIRF) (Figures 6B
and 6C and Movies S1 and S2). Within 5 min, numerous mobile
puncta enriched for both mCherry-PGRN and GFP-Sortilin
become apparent, consistent with endocytic vesicles (Figure 6B,
inset). Over the ensuing 10 min, nearly all PGRN is removed
from the cell surface of Sortilin-expressing cells (Figures 6B,
6C, and 6E, andMovies S1 and S2). By 18min, no diffuse plasma
membrane PGRN signal is visible, and limited signal remaining
near the cell surface is concentrated in mobile puncta consistent
with endosomes. The half-life for PGRN bound to Sortilin at the
cell surface is 4 min (Figure 6E). After 30 min, the mCherry-
PGRN signal visualized by confocal microscopy further from
the cell surface colocalizes extensively with the lysosomal
marker Lamp1 (Figure 6F).
The clearance of PGRN from the cell surface is dependent on
the cytoplasmic domain of Sortilin, because a truncated mutant
binds mCherry-PGRN, but there is little change in PGRN TIRFnance (SPR) analysis (BIAcore). PGRN (10–100 nM) was applied to a microchip
dicated; mean ± SEM.
el affinity chromatography from transfected cell conditioned medium, and then
s, in kDa, at left.
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Figure 2. Specificity of Progranulin Interaction with Sort1
(A) PGRN does not bind to Sortilin homologs SorLA or SorCS1, or to neurotensin receptor 2 (NTR2) in transfected COS-7 cells.
(B) The C terminus of PGRN is the Sortilin binding domain in PGRN. AP-PGRN, AP-PGRN-E (aa 494–593), or AP-PGRNDE (aa 18–493) was allowed to bind to
COS-7 cells transfected with a Sortilin expression vector. Whereas PGRN-E exhibits strong binding to Sortilin, PGRNDE does not bind to Sortilin.
(C) Scatchard plot of AP-PGRN-E or AP-PGRN binding to Sortilin-expressing COS-7 cells. KD, mean ± SEM, n = 4.
(D) Displacement of PGRN binding to Sortilin. COS-7 cells transfected with Sortilin vector were preincubated with 100 nM purified his-tagged PGRN, 100 nM
purified Sort1-ectodomain, 20 mM GST, 2 mM NT peptide, 50 mM NT peptide residues 1–6, 2 mM NT peptide residues 8–13, or 20 mM purified GST-tagged
Pro domain of NGF before addition of AP-PGRN at 4 nM. Cells were further incubated for another 2 hr before washing, fixation, and visualization of binding using
AP substrates.
(E) Binding from experiments as in (D) is quantitated. Data are mean ± SEM from 3–4 independent measurements. *p < 0.05 relative to No Addition, one-way
ANOVA.
Neuron
Sortilin-Mediated Endocytosis of Progranulin
658 Neuron 68, 654–667, November 18, 2010 ª2010 Elsevier Inc.
Neuron
Sortilin-Mediated Endocytosis of Progranulinsignal over 60 min (Figure 6C and Movie S3), consistent with
a half-life at the cell surface at least five times longer than that
for ligand bound to intact Sortilin. A portion of the GFP-Sortilin
protein initially colocalizing with PGRN ligand at the cell surface
later becomes clustered in mCherry-PGRN-positive puncta (Fig-
ure 6B andMovie S1), and there is a net decrease in GFP-Sortilin
signal within 400 nm of the plasma membrane. Clearance is not
as complete as for mCherry-PGRN (Figure 6B). As the mCherry-
PGRN ligand signal is cleared over 10 min, the GFP-Sortilin
receptor signal stabilizes and there is a recovery of the diffuse
plasma membrane signal, consistent with recycling of GFP-
Sortilin from endosomes to plasma membrane (Figure 6B and
Movie S1). The decreased TIRF signal for GFP-Sortilin at 37C
after exposure to PGRN requires the presence of bound ligand,
since there is little signal decrease in the absence of PGRN (Fig-
ure 6D and Movie S4). Thus, there is rapid endocytosis of extra-
cellular PGRN by cell surface Sortilin to COS-7 lysosomes.
We considered whether the vacuolar pattern of PGRN staining
observed in neurons of the frontal cortex and spinal motoneu-
rons (Figure 5) might reflect lysosomal accumulation of the
PGRN protein. Double immunohistochemistry for the lysosomal
marker Lamp1 and for PGRN reveals that a substantial fraction of
PGRN in frontal cortex is present in Lamp1-positive lysosomes
(Figure 6G).
Sortilin Controls PGRN Levels In Vivo
To consider the impact of this endocytic mechanism in vivo, we
examined PGRN levels in Sort1/ mice. PGRN immunoreac-
tivity in brain exhibits two species of 73 and 78 kDa due to differ-
ential glycosylation (Figures 7 and S6A), while PGRN in serum is
largely of 78 kDa (Figure 7D). In 7-month-old mice lacking
Sortilin, PGRN protein levels are strongly upregulated (Figures
7B–7E). The increase in total brain PGRN level is 2.5-fold (Figures
7B and 7C), while the increase of 78 kDa PGRN in brain and in
serum is 5-fold (Figures 7D and 7E). Because FTLD derives
from PGRN haploinsufficiency with a 50% decrease in PGRN
protein levels, the absence of Sortilin may fully normalize
PGRN levels. Indeed, GRN+/ mice lacking Sortilin expression
exhibit levels of PGRN protein that equal or exceed WT levels
(Figures 7F, 7G, S6B, and S6C). The protein changes are specific
for PGRN, in that levels of another Sortilin ligand, prosaposin
(Lefrancois et al., 2003; Zeng et al., 2009), are not altered (Fig-
ure S6E). While Sortilin deficiency increases PGRN level, abla-
tion of PGRN does not alter Sortilin level or proteolysis in brain
tissue (Figure S6D). The rapid endocytosis of PGRN by Sortilin
(Figure 6) is the likely cause for increased PGRN in Sort1/
mice. To consider an alternative transcriptional mechanism,
we assessed the level of PGRN mRNA in brain by quantitative
RT-PCR. No difference in PGRN mRNA levels occurs in(F) p75NTR does not affect PGRN binding to Sortilin. AP-PGRN at the indicated
transfected with p75NTR alone, or cotransfected with Sortilin and p75NTR, as in
(G) Binding analysis of PGRN to all five Vps10 family members by SPR analysis dem
detectable binding to SorCS1–3. PGRN (200 nM) was included in the perfusate
(H) Competitive SPR analysis of PGRN and proNGF to Sortilin. Between time point
as indicated. Between points 2 and 3, the chips were exposed to PGRN (200 nM) o
altered by prior incubation with proNGF.
Scale bars, 50 mm.Sort1/ versus WT mice (Figure S6F), supporting the hypoth-
esis that Sortilin endocytosis determines PGRN level in brain
and serum.
DISCUSSION
The major finding of this work is that Sortilin is a principal
neuronal binding site for the FTLD protein PGRN. In a stressed
nervous system, after production by activated microglial cells,
PGRN binds to Sortilin expressed on the neuronal cell surface.
Binding occurs via the C terminus of PGRN, in a manner that
may resemble NT binding to Sortilin (Quistgaard et al., 2009). A
dramatic consequence of such binding is the rapid endocytosis
of PGRN by Sortilin. In vivo, the absence of Sortilin raises PGRN
levels by 2.5- to 5-fold in different compartments. Given that
FTLD is caused by a 2-fold reduction of PGRN levels (Baker
et al., 2006; Cruts et al., 2006; Finch et al., 2009; Gass et al.,
2006; Ghidoni et al., 2008; Sleegers et al., 2009), the magnitude
of this change has clear pathophysiological consequences, and
PGRN deficiency in GRN+/ mice is fully normalized by deletion
of Sortilin expression (Figures 7F, 7G, and S6).
There are several mechanisms whereby PGRN/Sortilin inter-
action might alter neuronal function and contribute to FTLD-
TDP. Sortilin may function upstream to titrate PGRN levels
and/or downstream of PGRN to mediate its effects on cell func-
tion. To distinguish the relative importance of Sortilin upstream
versus downstream of PGRN will require the creation of FTLD-
TDP relevant models in which altering PGRN function changes
the outcome. Unfortunately, such an experimental model is not
yet established. The changes in brain and serum PGRN levels
in Sort1/ mice observed here demonstrate that Sortilin can
have an upstream effect to regulate levels of PGRN. However,
there is ample reason to believe that Sortilin’s primary effect is
downstream of PGRN, as a mediator or receptor for functional
effects in neurons. Sortilin is reported to possess signaling func-
tion in complex with p75NTR for proneurotrophin apoptotic
signaling (Domeniconi et al., 2007; Jansen et al., 2007; Nykjaer
et al., 2004; Teng et al., 2005). While we did not observe modu-
lation of PGRN binding to Sortilin by p75NTR, proneurotrophin
action may be altered in a more complex in vivo setting. Specif-
ically, since proNGF and PGRN can both bind to Sortilin (Figures
2D, 2E, and 2H), PGRN might rescue cells otherwise subject to
proneurotrophin-induced cell death through Sortilin/p75NTR.
Displacement of PGRN by proNGF is of low potency so it may
be indirect or allosteric, and therefore highly dependent on
cellular context. Further study of proneurotrophin-related effects
under a range of conditions may be revealing. However, it
remains at least equally likely that PGRN signals via Sortilin inde-
pendently of proneurotrophins.concentration was allowed to bind COS-7 cells transfected with Sortilin alone,
dicated.
onstrated strong PGRNbinding to Sortilin, very weak binding to SorLA, and no
during the interval from 100–550 s.
s 1 and 2, Sortilin chips were exposed to saturating proNGF (1000 nM) or buffer,
r proNGF (1000 nM). Binding of PGRNduring the 2-3 interval is not substantially
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Figure 3. Sortilin Is an Endogenous Brain PGRN Binding Site
(A) Sortilin expression in cortical neuron culture lysate by immunoblot.
(B) AP-PGRN binding to cortical neuronal cultures grown for indicated times.
Scale bar, 50 mm.
(C) AP-PGRN-E exhibits strong binding to cortical neurons (21 DIV), while
PGRNDE binding is minimal at 10 nM. Scale bar, 50 mm.
(D) Brain lysate of WT (+/+) or Sort1 knockout (/) mice were incubated with
purified GST or GST-PGRN-E (aa 494–593) protein. After further incubation
with glutathione beads, the pulldown products were washed and blotted
with mouse anti-Sortilin antibodies. The trace immunoreactivity in the lysate
of the Sort1/ sample is derived from a truncated, nonfunctional protein
(Jansen et al., 2007 and data not shown). Mr markers are shown to the right;
100 kDa in the top panel, and 37 kDa plus 25 kDa in the bottom panel.
(E) AP-PGRN-E (1 nM) binding to cultured mouse neurons (21 DIV) from
Sort1+/ and Sort1/ mice. Scale bar, 50 mm.
(F) Quantification of AP-PGRN-E binding to cultured mouse neurons from
Sort1+/ and Sort1/ mice. The gray box represents nonspecific binding
assessed in the presence of 200 nM his-PGRN as in Figure S1B. Mean ±
SEM, **p < 0.01, one-way ANOVA.
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Figure 4. Levels of Extracellular Progranulin Are Reduced by
Cellular Sortilin
(A) HEK293T cells were cotransfectedwith humanPGRN expression construct
plus pcDNA vector control, SorLA, or various Sortilin expression constructs.
The conditioned media (CM) and cell lysates (Cells) were collected 5 days after
transfection and immunoblotted for PGRN and Sortilin.
(B) Quantification of PGRN level in the CM or in the cell lysate (Cells) for exper-
iments in (A) expressed as percentage of pcDNA control. Mean ± SEM,
**p < 0.01, one-way ANOVA.
(C) HEK293T cells were cotransfected with human, full-length Sortilin expres-
sion vector plus pcDNA control vector or PGRN expression vector. Immuno-
blot for Sortilin protein shows that the majority is cell associated and not
shed, regardless of PGRN coexpression.
Neuron
Sortilin-Mediated Endocytosis of Progranulin
660 Neuron 68, 654–667, November 18, 2010 ª2010 Elsevier Inc.Separate from signaling at the cell surface, PGRN may have
intracellular functions dependent on endocytosis by neuronal
Sortilin and delivery to lysosomes. Importantly, immunologically
intact PGRN accumulates within the lysosomal compartment of
COS-7 cells and neurons. In healthy or FTLD-TDP human brain,
PGRN is most prominent in microglial cells, but is also present
in puncta within the cytoplasm of neurons (Mackenzie et al.,
2006), and these appear most consistent with lysosomes. These
observations raise the possibility that PGRN functions within
autophagosomal/lysosomal pathways. Endocytosis and lyso-
somal delivery of another Sortilin ligand, prosaposin, serves to
enhance lysosomal function rather than simply degrading the
ligand (Lefrancois et al., 2003; Zeng et al., 2009).
Figure 5. Localization of Sortilin and PGRN in Different CNS Cell Types
(A) Double immunohistochemistry for PGRN (green) and Sortilin (red) in adult mouse frontal cortex. The boxed area in the merge is shown at the right. Scale bar,
7 mm.
(B) Anti-PGRN staining of mouse frontal cortex from WT and Sort1/ mice. In both cases vacuolar staining is prominent in neurons, and there is a trend to
decreased vacuolar localization and increased diffuse neuropil staining in the Sortilin null samples. Scale bar, 7 mm.
(C) Anti-Sortilin staining of human frontal cortex from neurological healthy control and an FTLD-TDP case with PGRN mutation. Scale bar, 30 mm for top panels
and 10 mm for bottom panels.
(D) Sortilin immunohistochemistry of the ventral horn in the mouse L5 spinal cord shows significant expression of Sortilin in motor neurons. Scale bar, 50 mm.
(E and F) Immunohistochemistry for PGRN in the ventral horn (VH) of L5 spinal cord transverse sections frommice that had unilateral sciatic nerve resection 7 days
previously. Injury-induced PGRN expression is detected on the axotomized side, but not on the uninjured side in (E). Significant colocalization of injury-induced
PGRN with the microglial marker (Iba1) is observed on the axotomized side (blue arrows in F), but not on the uninjured side. Less intense vacuolar PGRN immu-
noreactivity is detected in motoneurons (white arrows in F). Scale bars, 50 mm in (E) and 18 mm in (F).
(G) The conditioned medium and cellular fraction of C13-NJ microglial cell line cultures were immunoblotted for PGRN and for Sortilin. PGRN secretion is
prominent, and there is little Sortilin immunoreactivity.
Neuron
Sortilin-Mediated Endocytosis of ProgranulinUnder this hypothesis, Sortilin binding is crucial to provide
neuronal competence for TDP-43 clearance via autophagoso-
mal/lysosomal mechanisms. Sortilin is a member of the Vps10
family (Willnow et al., 2008), members of which are required for
sorting to the lysosomal vacuole in yeast (Cooper and Stevens,
1996). Sortilin is known to participate in the delivery of extracel-
lular prosaposin and intracellular Golgi-derived cathepsins tolysosomes (Canuel et al., 2008; Lefrancois et al., 2003; Ni and
Morales, 2006; Zeng et al., 2009). PGRN is coregulated with
lysosomal genes (see the Supplemental Data in Sardiello et al.,
2009). We and others (Ahmed et al., 2010) have observed accel-
erated brain lipofuscinosis inmice lacking PGRN. Of relevance to
FTLD, the clearance of cytoplasmic TDP-43 depends at least in
part on autophagy (Caccamo et al., 2009; Ju et al., 2009;Neuron 68, 654–667, November 18, 2010 ª2010 Elsevier Inc. 661
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Figure 6. Rapid Endocytosis of PGRN by Sortilin
(A) COS-7 cells expressing Sortilin were incubated with conditioned media containing mCherry-tagged PGRN at 4C and confocal images were acquired after
staining with anti-Sortilin antibodies. A magnified view of the boxed region is provided by the inset. Colocalization at the cell surface was seen at 4C.
(B) Sortilin mediates endocytic trafficking of PGRN. GFP-Sortilin-expressing COS-7 cells were incubated with mCherry-PGRN at 4C and then shifted to 37C for
live imaging by TIRF microscopy (see Movie S1). The insets provide magnified views of the boxed regions. After 4 min at 37C, mCherry-PGRN is localized to
puncta with GFP-Sortilin (arrow). By 8 min, most mCherry-PGRN diverges into vesicles that lack GFP-Sortilin (arrow).
(C) Endocytosis of PGRN by Sortilin requires the cytoplasmic domain of Sortilin. COS-7 cells expressing Sortilin or pDisplay-Sort1 were incubated with media
containing mCherry-PGRN washed and imaged by TIRF microscopy for the indicated times. Near complete internalization of mCherry-PGRN is seen in the
Sortilin-expressing cells by 18min at 37C (Movie S2), whereas pDisplay-Sort1-expressing cells show persistent mCherry-PGRN signal near the cell surface after
60 min (Movie S3).
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Figure 7. PGRN Levels Are Increased in Mice Lacking Sortilin
(A) WT and GRN/ mouse brain lysate was analyzed by anti-PGRN immunoblot.
(B) Tissue lysate collected from the cerebral cortex of 7-month-old mice was subjected to SDS-PAGE and anti-PGRN immunoblot. Two PGRN bands are seen at
78 kDa (band A) and at 73 kDa (band B); both bands increase in the Sort1/ samples compared to those of WT.
(C) Quantification of PGRN level (bands A, B, and A+B) in the cortical lysate, normalized to GAPDH immunoreactivity. Sort1/, n = 4 mice; WT, n = 5. Mean ±
SEM, **p < 0.01, one-way ANOVA.
(D) Serum samples from 7-month-old Sort1/ and WT mice were collected, stripped of albumin and IgG, and immunoblotted for PGRN and transferrin. Serum
levels of PGRN were increased in the Sort1/ mice compared to littermate WT mice.
(E) Quantification of PGRN level in the serum normalized to transferrin level. For both genotypes, n = 4 mice. Mean ± SEM, **p < 0.01, one-way ANOVA.
(F) Serum samples from 2-month-old mice were obtained from the indicated genotypes and analyzed by anti-PGRN immunoblot, with anti-thrombin III immu-
noblot as a loading control.
(G) Quantification of PGRN level in the serum normalized to anti-thrombin III level. For all genotypes, n = 4 mice. Mean ± SEM; *p < 0.05; **p < 0.01; one-way
ANOVA.
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Sortilin-Mediated Endocytosis of ProgranulinUrushitani et al., 2010; Wang et al., 2010). Ubiquitin coaccumu-
lation with TDP-43 aggregates may reflect disrupted balance
between proteosomal pathways, macroautophagy, and chap-
erone-mediated autophagy pathway.
In this regard, it may be relevant to consider thosemutations in
Valosin-Containing Protein (VCP), which are known to cause
FTLD plus myopathy and Paget disease (Custer et al., 2010; Ju
et al., 2009; Watts et al., 2004). The accumulation of TDP-43
and ubiquitin aggregates in brain of these rare cases is similar
to that in more common PGRN mutant cases. Since VCP has
a prominent role in autophagy, the PGRN pathway and the
VCP pathway may overlap as intracellular constituents are(D) GFP-Sortilin-expressing cells were incubated without mCherry-PGRN at 4Ca
S4). The GFP-Sortilin distribution near the cell surface is stable compared with c
(E) The background-corrected mCherry fluorescence intensity relative to time zer
PGRN signal from Sortilin-expressing cells is the mean ± SEM for n = 9, and the
(F) Endocytosed PGRN localizes to lysosomes. Sortilin-expressing COS-7 cells w
washed and shifted to 37C. Cells were fixed at indicated times and stained wit
a laser-scanning confocal microscope.
(G) Endogenous brain PGRN is localized to lysosomes. Sections of adult frontal co
colocalization demonstrates that many PGRN-reactive puncta are lysosomes in
Scale bar, 10 mm.sorted to lysosomes. Both PGRN and VCP might function to
clear TDP-43 aggregates via autophagy.
As noted above, PGRN can be converted proteolytically into
smaller GRN peptides (Zhu et al., 2002). In the extracellular
space, this conversion can be mediated by elastase and
inhibited by secreted leukocyte protease inhibitor (SLPI). Lyso-
somal localization of PGRN may also influence conversion
from PGRN to GRN, and therefore the balance between PGRN
and GRN function. Such conversion may have downstream
effects on PGRN biology and the pathophysiology of FTLD. In
order to separate these possibilities further, in vivo neuronal
studies of GRN versus PGRN activity will be required.nd theGFP-Sortilin signal was imaged using TIRF for the indicated times (Movie
ells with ligand in (B).
o is plotted as a function of time from experiments as in (B)–(D). The mCherry-
apparent half-life is 4 min.
ere incubated with mCherry-PGRN (red in merge) on ice for 4 hr before being
h mouse anti-Lamp1 antibodies (green in merge). Images were obtained with
rtex were double stained for anti-PGRN (green) and anti-Lamp1 (red). Extensive
these two examples.
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Neuron
Sortilin-Mediated Endocytosis of ProgranulinIt is clear from the present data that the interaction of PGRN
with Sortilin-mediated endocytosis significantly reduces steady-
state PGRN levels. The magnitude of this reduction is at least as
great as that of those PGRNmutations causing FTLD-TDP. Thus,
Sortilin binding provides a potential therapeutic site to alter
PGRN-dependent pathways and alleviate TDP-43 pathology.
It is clear that microglial cells are a major source of PGRN
production. For example, activated microglia in the vicinity of
axotomized motoneurons strongly induce PGRN after sciatic
nerve injury. From this observation, it follows that characterizing
the mechanisms of microglial PGRN induction or the selectivity
of PGRN for subsets of microglia may reveal additional means
to modulate the course of FTLD-TDP.
BecauseneitherGRN+/ norGRN/miceexhibit an FTLD-like
phenotype (Kayasuga et al., 2007; Yin et al., 2010) (data not
shown), this human inherited disease cannot be modeled simply
in rodent. Although peripheral axotomy shifts TDP-43 from the
nucleus to the cytoplasm of motoneurons (Moisse et al., 2009;
Sato et al., 2009) andmight sensitize toFTLD/ALS-like pathology,
neither GRN/ nor Sort1/ mice have detectable motoneuron
loss or ventral root axonal degeneration after this perturbation
(Figure S4). Future functional studies of Sortilin in PGRN biology
will require development of robust rodent models for PGRN-
dependent neurodegeneration. Nevertheless, our work impli-
cates Sortilin-mediated PGRN endocytosis as a key pathway
for further study in FTLD pathophysiology.EXPERIMENTAL PROCEDURES
Animals, Cell Lines, Antibodies, and Human Tissue
The Sort1/mouse line has been described (Jansen et al., 2007) and studies
here utilized mice backcrossed for more than nine generations to C57BL6. The
Sort1/mice are generated by deletion of a critical exon encoding a portion of
the b-propeller domain. Although trace levels of immunoreactivity of smaller
size are detectable in the Sort1/ strain, none of the mutant protein folds
appropriately or reaches the cell surface (data not shown). GRN mutant
mice were obtained from the RIKEN Bioresource Center (Kayasuga et al.,
2007). Both littermate controls and C57BL6 mice were used as WT control.
COS-7 andHEK293T cells were obtained fromATCC. The following antibodies
were used in the study: mouse anti-Sortilin (612101) antibody from BD Biosci-
ences, goat anti-Sortilin (BAF2934) and rabbit anti-Sortilin (ab16640) antibody
from Abcam, mouse anti-human PGRN (mAB2420) and sheep anti-mouse
PGRN (AF2557) antibodies from R&D Systems, mouse anti-Flag M2 anti-
bodies, rabbit anti-Myc, and mouse anti-GAPDH (G8795) antibodies from
Sigma-Aldrich, rat anti-Transferrin (sc-33731) and goat anti-Actin (sc-1616)
from Santa Cruz Biotech, rabbit anti-Iba-1 (019-19741) from Wako, mouse
anti-NeuN (Mab377) from Millipore, rabbit anti-TDP43 antibody (12892-1-AP)
from Protein Tech, mouse anti-Beta III tubulin (G712A) from Promega, mouse
anti-Lamp1 antibody from BD biosciences (611043), anti-Prosaposin from
Abcam (ab68466), and anti-Prosaposin from Abgent (AP7398c).
Human brain tissue from neurologically healthy and FTLD-U cases with
PGRN mutations was collected as described (Baker et al., 2006). Paraffin-
embedded frontal cortex from one affected individual from each of the six
families described previously (Baker et al., 2006) was studied for Sortilin
localization.
Plasmid Constructs and Recombinant Proteins
Human PGRN in pCMV-Sport6 vector was obtained from Open Biosystems.
To generate AP fusion proteins, human PGRN coding sequence for mature
peptides (aa 18–593) and corresponding fragments were amplified and ligated
to the pAP5-tag vector (GenHunter, Nashville, TN) digested with restriction
enzymes XhoI and PmeI. AP-PGRN fusion proteins were expressed in664 Neuron 68, 654–667, November 18, 2010 ª2010 Elsevier Inc.HEK293T cells and purified as described for other proteins (Fournier et al.,
2001; Hu et al., 2005; Laure´n et al., 2009). Flag- and his-tagged PGRN were
cloned in pSectag2 vector (Invitrogen). An expression vector for mCherry-
tagged PGRN was generated in the pAP5 vector by replacing AP sequence
with mCherry sequence using HindIII and XhoI followed by inserting mature
human PGRN (aa 18–593) coding sequence using XhoI and PmeI.
Human Sortilin in a mammalian expression vector was obtained from
Origene. Myc-his-tagged, full-length, mature human Sortilin (aa 60–831) and
Myc-his-tagged Sortilin extracellular domain (ecto, aa 60–725) constructs
were generated by replacing AP coding sequence in the pAP5 vector with
Myc-his-Sortilin or Myc-his-Sort1-ecto coding sequences after the Pro
domain. Myc-his-Sort1-ecto plasmid was then transfected into HEK293T cells
andMyc-his-Sort1-ecto protein was purified from the conditionedmedia using
Ni++ beads. To generate fusion protein of Sort1-ectodomain with the platelet
derived growth factor receptor (PDGFR) transmembrane domain, Sort1-ecto-
domain (aa 60–725) was cloned into the pDisplay vector (Invitrogen) using SfiI
and XmaI sites. GFP-Sortilin construct was engineered from pEGFP-C1 vector
with the signal peptide of IgG followed by GFP and residues 60–831 of Sortilin
cloned at XhoI and XmaI sites.
The AP-NT8-13 construct wasmade by cloning sequence of human NT resi-
dues 8–13 into pAP5 vector using XhoI and ApaI sites. SorLA expression
constructs were a gift from Dr. Wolfgang Hampe at Inst. fu¨r Biochemie und
Molekularbiologie and Dr. Thomas E. Willnow at Max-Delbrueck Center for
Molecular Medicine. Sort1-mut vector was a gift from Dr. Claus M. Petersen
at University of Aarhus (Nielsen et al., 2001). Human NTR1 construct was
a gift from Dr. Jean Mazella from Institut de Pharmacologie Mole´culaire et
Cellulaire, Sophia Antipolis, Valbonne, France. SorCS1 and NTR expression
constructs in pCMV-Sport6 were obtained from Open Biosystems.
For soluble protein production, expression plasmids were transfected into
HEK293T cells and conditioned media were collected after 5 days. Flag-
PGRN was purified from the conditioned media using mouse anti-Flag conju-
gated beads fromSigma-Aldrich and his-PGRNwas purified using Ni++ beads
from Invitrogen.
To generate GST-fusion proteins, a PGRN fragment (aa 494–593, PGRN-E)
and the Pro domain of NGF were cloned in the pGEX6P-1 vector (GE Health-
care). GST fusion protein was expressed in BL21 (DE3) E. coli cells and purified
using glutathione beads (GE Healthcare).Binding Assays and Expression Cloning
AP-PGRN binding assays and cDNA library screening were performed with
transfected COS-7 or mouse cortical neurons, as described for other ligands
(Fournier et al., 2001; Hu et al., 2005; Laure´n et al., 2009). Conditioned media
with AP ligands were incubated with untransfected or receptor-transfected
COS-7 cells for 2 hr at room temperature before fixation and heat inactivation
of endogenous AP at 65C overnight. Bound AP to COS-7 cells was measured
using NIH image software.
We screened 225,000 clones of an arrayed adult mouse brain cDNA library
(Origene) by transfecting COS-7 cells with arrayed pools of 100 clones, and
inspecting for those rare cells transfected with a cDNA conferring to AP-
PGRN binding, as for other ligands (Laure´n et al., 2009). DNA preparation
from amplified pools of 100 cDNA clones was by the Iowa State University
DNA Facility. We also examined individual clones from a 352-member pre-
existing collection of expression vectors for transmembrane proteins (GFC,
Origene) for AP-PGRN binding (Laure´n et al., 2009).Neuronal Cultures and Neuronal Binding Assays
Cortical neurons and hippocampal neurons isolated from E18 rats and E17
mice were cultured as described (Laure´n et al., 2009), omitting laminin. Live
neurons were incubated with conditionedmedia containing AP-fusion proteins
at 4C for 1 hr prior to washes and fixation. BoundAPwasmeasured by obtain-
ing images at 203 and 103 measuring binding using NIH image software as
above. Displacement assays were conducted by incubating neurons with
the competitor (untagged ligand) for 30 min at 4C, followed by incubation of
AP ligand with the competitor. Neuronal cell lysates were prepared in RIPA
buffer. Standard western blot procedures for the Li-Cor Odyssey system
were followed.
Neuron
Sortilin-Mediated Endocytosis of ProgranulinBrain Lysates, Pulldown, and Immunoblots
Immunoblot and affinity chromatographymethods have been described (Four-
nier et al., 2001; Hu et al., 2005; Jansen et al., 2007; Laure´n et al., 2009; Nykjaer
et al., 2004). Conditioned media with Flag-PGRN or Myc-his-Sort1-ectodo-
main were mixed together and incubated with anti-Myc antibody conjugated
beads (Santa Cruz) or mouse anti-Flag antibody conjugated beads (Sigma).
After incubating at 4C for 2 hr, the beads were washed four times with PBS
buffer. For brain lysate pulldown, adult mouse brain was lysed in 6 ml PBS
buffer with 1% Triton. Twomilliliters of lysate were then incubated with purified
GST or GST-PGRN-E (aa 494–593) fusion protein. The lysates were further
incubated with glutathione beads for an additional 2 hr and then the beads
were washed with lysis buffer.
To determine various protein levels in samples from the various genotypes,
7-month-old or 2-month-old mice were transcardially perfused with cold PBS,
cortically dissected, and homogenized in RIPA buffer. Extractswere separated
by 4%–20% SDS-PAGE and immunoblotted using sheep anti-PGRN, rabbit
anti-Sortilin, rabbit anti-prosaposin, and GAPDH antibodies. Immunoreactive
bands were quantified using Li-Cor Odyssey v3.0 software.
Serum Analysis
Blood was collected from the cardiac right ventricle of deeply anesthetized
animals. The collected blood was kept at RT for 15 min to coagulate and
was then centrifuged at 1000 3 g for 15 min. Albumin and IgG were removed
(Calbiochem #122642 according to manufacturer’s instructions). Equal
amounts (35 mg) of protein were then subjected to SDS-PAGE on a 4%–
20% gel and immunoblotted with the appropriate antibodies.
RT-PCR
Cortical tissue was dissected from 7-month-old mice and was snap frozen in
liquid nitrogen. RNA was extracted from 50 mg of tissue using RiboPure Kit
(Ambion #AM1924). The extracted RNA was subjected to quantitative PCR
using TaqMan RNA-to-CT1 step kit (Applied Biosystems), with two GRN-
specific probes (Mm01245914_g1, Mm00433848_m1 from Applied Biosys-
tems) and control probes (GAPDH and actin).
Glycosidase Digestion of Brain Tissue
Cortical tissue from mice was homogenized in TBS. The resulting lysates
(70 mg) were subjected to digestion with PNGaseF (New England Biolabs) or
Endo-a-N-Acetylgalactosaminidase Glycosidase (New England Biolabs)
treatment for 1 hr at 37C as directed by the manufacturer. The mixtures
were then subjected to methanol/chloroform (4:1) precipitation and the result-
ing material was resuspended in 23 SDS-PAGE loading buffer and run on
a 4%–20% polyacrylamide gel for immunoblots.
Sciatic Nerve Injury and Analysis
Mice were anesthetized using 4% isofluorane and the sciatic nerve was
exposed at the lower hip level. The sciatic nerve was ligated 4 mm below
the sciatic foramen of the pelvic girdle with 5-0 vicryl and a 2.5 mm segment
was resected distal to the ligation. The mice were given an injection of ampi-
cillin, buprenorphine, and saline subcutaneously postsurgery.
Three weeks after surgery, the animals were deeply anesthetized and then
perfused with PBS followed by 4% paraformaldehyde in PBS (pH 7.2). The
gelatin-embedded L5 spinal cord tissue was processed into 30 mm sections
using a vibrating microtome and stained with the indicated primary antibodies
using appropriate Alexa secondary antibodies (Invitrogen).
For ventral root axon profile analysis, L5 ventral roots were dissected, post-
fixed in 2.5% glutaraldehyde, and embedded in Epon. Semithin 500 nm
sections were stained with toluidine blue. Total intact axon profiles per root
were counted, without knowledge of mouse genotype.
Immunohistochemistry of Mouse and Human Frontal Cortex
Seven-month-old mice were deeply anesthetized and then perfused with PBS
followed by 4% paraformaldehyde in PBS (pH 7.2). Thereafter, costaining of
tissue was conducted using conventional immunohistochemical procedures
(block with 10% serum and permeabilize with 0.1% Triton X-100). For immu-
nofluorescent staining, the tissue was imbedded in gelatin and processed
into 35 mm sections using a vibrating microtome.DAB staining of paraffin-embedded human frontal cortex samples was con-
ducted using mouse anti-Sortilin (BD biosciences) and the ABC amplification
system (Vector Labs), as per manufacturer’s instructions.
TIRF Microscopy
In brief, COS7-cells were transfectedwith GFP-Sortilin and cultured for 3 days,
or cotransfected with GFP + human Sortilin or GFP + pDisplay-Sortilin and
cultured for 16–36 hr prior to conducting experiments. The cells were incu-
bated on ice 10min prior to addition of ligand, to attenuate endocytosis. There-
after, mCherry-PGRN medium was added to the cells, which were incubated
for 1–2 hr on ice andwashed three timeswith ice cold HBH. The cells were then
imaged at 4 s intervals for 30–60min at 37C using a 633 objective. The details
of the TIRF microscopy were as described (Zoncu et al., 2009).
SEC Fractionation
The size exclusion chromatography (SEC) data were collected with a 25 ml
Superdex 200 SEC column (GE Healthcare) and an AKTA high-performance
liquid chromatography system (GE Healthcare) at a flow rate of 0.5 ml min1
at 4C. Aliquots of AP fusion protein fractions from the SEC separation were
incubated with p-Nitrophenyl Phosphate (PNPP) substrate (Sigma N1891)
and the absorbance was measured at 405 nm using Victor 3V multilabel
counter (Perkin Elmer). Fractions from the mCherry-PGRN fractionation were
assessed for fluorescence (Ex 560/Em 615) using Victor 3V multilabel counter
(Perkin Elmer).
SPR
The expression, purification (>95%), and crystallization of soluble Sortilin has
been described (Quistgaard et al., 2009). SPR analysis was performed using
a BIAcore 3000 instrument (BIAcore Sweden) as previously described (Munck
Petersen et al., 1999). In brief, soluble Sortilin was immobilized at a density of
0.0952 pmol/mm2 on a CM5 sensor chips. PGRN was dialysed against 10 mM
HEPES (pH 7.4), 150 mM NaCl, 1.5 mM CaCl2, 1 mM EGTA, and 0.005%
surfactant P20 (running buffer), and 10–100 nM of the ligand was injected
(5 ml/min) through the flow cell at 20C. After 600 s, running buffer containing
PGRN was substituted with buffer lacking the ligand, allowing for determina-
tion of both the association and dissociation constants. The binding response
is expressed in relative response units, i.e., the difference in response between
the immobilized protein flow cell and a corresponding control flow cell. Kinetic
parameters were determined using the BIAevaluation 3.0 software.
To compare alternate Sortilin family proteins, equal amounts of soluble
Sortilin, SorLA, SorCS1, SorCS2, or SorCS3 proteins (>95%) were immobi-
lized on a CM5 chip and remaining coupling sites were blocked with 1 M etha-
nolamine. Sample and running buffer was 10 mM HEPES, 150 mM (NH4)2SO4,
1.5 mM CaCl2, 1 mM EGTA, and 0.005% Tween-20 (pH 7.4). PGRN was
applied at 200 nM for all receptors.
To test for competitive binding of PGRN and proNGF to Sortilin, the Sortilin
chip was initially incubated with 1000 nM proNGF prior to injection with
a mixture of PGRN (200 nM) and proNGF (1000 nM), and the signal was
compared to binding of PGRN (200 nM) alone. The sensor chip was regener-
ated in a 10 mM glycine-HCl buffer after each analytic cycle. The SPR signal
was expressed in relative response units, as the response obtained in a control
flow channel was subtracted.
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